Business Context and Reporting Period
Company: Anavex Life Sciences Corp.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2011
Status: Development Stage Company (No revenue since inception in 2004)
Operations: Biopharmaceutical company developing proprietary drug targets for central nervous system diseases (e.g., Alzheimer's) and cancer. Lead candidate ANAVEX 2-73 entered first Human Clinical Trials in Q1 2011.
Key Financial Metrics
| Metric | Six Months Ended March 31, 2011 |
Six Months Ended March 31, 2010 |
Balance Sheet March 31, 2011 |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(4,306,965) | $(2,162,643) | N/A |
| Accumulated Deficit | N/A | N/A | $(26,203,039) |
| Cash and Cash Equivalents | N/A | N/A | $3,641 |
| Working Capital Deficit | N/A | N/A | $(1,231,948) |
| Total Current Liabilities | N/A | N/A | $1,293,589 |
| Debt (Promissory Notes) | N/A | N/A | $200,000 |
| Cash Used in Operating Activities | $(1,672,903) | $(1,830,954) | N/A |
| Cash Provided by Financing Activities | $1,411,875 | $1,624,470 | N/A |
Material Changes vs. Prior Period
- Net Loss Increase: Net loss for the six months ended March 31, 2011, increased by approximately $2.15 million compared to the prior year period. This was driven by significant non-cash charges and increased operating expenses.
- Expense Drivers:
- Consulting Fees: Increased by $647,013 (to $1.67M) due to expanded management infrastructure and stock-based compensation.
- Debt Conversion Expense: A one-time charge of $504,160 was recorded for the induced conversion of convertible promissory notes.
- Loss on Debt Extinguishment: Recorded a loss of $198,738 on the settlement of interest-bearing notes.
- Loss on Accounts Payable Settlement: Recorded a loss of $249,090 on the settlement of accounts payable via share issuance.
- Debt Reduction: Significant reduction in promissory notes payable (from $2.49M to $200k) achieved through conversion to equity and settlement.
- Cash Position: Cash decreased by $261,028 to a critically low $3,641, despite financing inflows, due to high operating burn.
Outlook, Risks, and Management Commentary
- Going Concern: The filing explicitly states substantial doubt about the company's ability to continue as a going concern. The company has an accumulated deficit of over $26 million and expects to incur further losses.
- Capital Requirements: Management estimates a cash requirement of approximately $10 million for the next 12 months to fund clinical trials for ANAVEX 2-73 and other R&D activities.
- Financing Strategy: The company relies on equity and debt financing. Subsequent to the period end (April/May 2011), the company entered into agreements for $1 million in convertible debentures and raised additional equity.
- Risk Factors:
- Failure to secure additional financing could force the company to delay or cease operations.
- High risk associated with clinical trials and regulatory approval for drug candidates.
- Stock is classified as a "penny stock" with limited liquidity on the OTC Bulletin Board.
Investor Verification Checklist
- Cash Runway: Verify current cash balance (reported as $3,641) against immediate obligations to assess immediate solvency risk.
- Financing Status: Confirm the closing of the $1 million convertible debenture tranche and any subsequent equity raises mentioned in subsequent events.
- Dilution Impact: Review the impact of recent debt-to-equity conversions and new warrant issuances on existing shareholder ownership.
- Clinical Milestones: Monitor the progress and results of the Phase I clinical trials for ANAVEX 2-73, which are critical for future valuation.
- Related Party Transactions: Review Note 5 for significant consulting fees and amounts owed to directors/officers ($146,142 outstanding).